Due to its ability to balance blood sugar and control appetite, analog medications have been approved to treat both type 2 diabetes and obesity
On October 22, 2024, Novo Nordisk submitted a nomination to the FDA, arguing that semaglutide products belong on the Demonstrable Difficulties for Compounding (DDC) list due to the complexities associated with their formulations, delivery mechanisms, dosage forms, achievement of bioavailability, compounding processes, and physicochemical and analytical testing. The FDA has yet to make a final decision on whether to ban compounded versions of semaglutide
FAQ Answer: Semaglutide 3 mg Tablet is used as an initiation dose for type 2 diabetes management and blood sugar control
Erbil D, Eren CY, Demirel C, et al
In the study by Li et al., there was no significant difference between low doses and high doses of ALA, indicating that the benefits of ALA are not dose-dependent [105]
Renal function is another important consideration
